IDEXX Laboratories (NASDAQ:IDXX) Q2 2026 EPS of $4.27 Beats by 6.1%, Full-Year Outlook Raised

IDEXX Laboratories (NASDAQ: IDXX) reported Q2 2026 EPS of $4.27, beating the $4.02 consensus estimate by 6.1%, while revenue of $1,217 million grew 10% year over year. Operating margin expanded 140 basis points to 35.0%, and the company raised its full-year EPS and revenue outlook on the strength of recurring diagnostics growth and margin improvement.

Q2 2026 Results

• Revenue: $1,217 million, up 10% as reported and 9% organic year over year, versus approximately $1,106 million in Q2 2025.
• EPS: $4.27 as reported, up 18% from $3.62 in the prior-year period, including $0.14 per share in tax benefits from share-based compensation.
• Operating income: $426 million, up 14.1% year over year, with operating margin of 35.0%, up 140 basis points as reported.
• CAG Diagnostics recurring revenue: grew 11% as reported and 10% organic, with international regions posting 14% reported growth and the U.S. delivering 10% reported growth.
• IDEXX inVue Dx installed base: surpassed 9,000 instruments, supported by over 1,600 placements during the quarter.

What Drove the Results

EPS of $4.27 beat the $4.02 consensus by $0.25, or 6.1%. Revenue of $1,217 million grew 10% as reported, with the growth led by Companion Animal Group revenue up 9% as reported and organic, Water revenue up 15% as reported and 13% organic, and Livestock, Poultry and Dairy revenue up 11% as reported and 9% organic.

Operating margin of 35.0% expanded 140 basis points as reported, supported by recurring revenue volume gains, operational productivity, and net price realization, even as operating expenses grew 10% as reported. VetLab consumables generated 15% reported and 14% organic revenue growth, and reference laboratory services grew 11% reported and 10% organic, both driven by higher testing volumes and net new customer gains. Veterinary software, services, and diagnostic imaging revenues grew 12% on a reported and organic basis, with diagnostic imaging systems recording a record quarter of installations.

CEO Mike Erickson attributed the quarter's performance to the company's Technology for Life strategy, with deeper customer adoption across the Catalyst, Fecal Dx, and IDEXX inVue Dx platforms supporting higher diagnostic utilization.

Updated 2026 Guidance

IDEXX narrowed its full-year revenue guidance to $4,700 million to $4,745 million, up $5 million at the midpoint, reflecting CAG Diagnostics recurring revenue outperformance net of a $15 million foreign exchange headwind. Full-year organic revenue growth guidance was raised to 8.5% to 9.7%, up 0.4 percentage points at the midpoint. The company increased its full-year EPS outlook to $14.69 to $14.94, representing reported growth of 12% to 14%, with the midpoint increase of $0.14 per share driven by operational performance. Full-year capital expenditure guidance stands at approximately $180 million, with operating cash flow projected at 110% to 120% of net income and free cash flow at 90% to 100% of net income.

Wall Street View

Following the earnings release, UBS analyst Andrea Alfonso maintained a Neutral rating and raised the price target to $670 from $620. Citigroup analyst Daniel Grosslight also maintained a Neutral rating and raised the price target to $670 from $650. Both firms lifted their targets after the quarter's results and updated guidance, though neither moved off their neutral stance on the stock. Shares closed at $584.78 on Wednesday, August 5, down -0.56% while the S&P 500 declined -0.20%.

Investor Takeaway

The Q2 beat and raised full-year EPS midpoint of $14.82 confirm that IDEXX's recurring diagnostics model continues to compound above sector growth levels, with the inVue Dx installed base now exceeding 9,000 units providing a structural volume driver into the second half of 2026. The foreign exchange drag of approximately $15 million on revenue and $0.22 per share on EPS represents a meaningful offset to underlying operational performance, making organic growth metrics the more relevant benchmark for investors assessing the durability of IDEXX's revenue trajectory.